The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Iterum Therapeutics plc (“Iterum” or “the Company”) (NASDAQ: ITRM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between November 30, 2020 and July 23, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before October 4, 2021.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Iterum’s New Drug Application (“NDA”) for sulopenem failed to include sufficient data to support the drug’s approval for the treatment of uncomplicated urinary tract infections (“uUTIs”) in adult women. It was unlikely the FDA would approve the Company’s NDA as it was submitted. The Company downplayed the deficiencies in its NDA. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Iterum, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210806005501/en/